Eli Lilly's new weight-loss pill Foundayo approved for use in the UK
The UK's medicines regulator has approved Foundayo, an oral weight-loss pill developed by Eli Lilly, opening the door to a needle-free option for obesity treatment and adding a new dimension to the global interest that has built around the GLP-1 drug class in recent years.
Eli Lilly is the drugmaker behind Mounjaro (tirzepatide), the injectable medication that has drawn enormous global attention in recent years. Mounjaro and similar GLP-1 receptor agonist drugs support weight loss by suppressing appetite and prolonging feelings of fullness; these medications have driven a striking shift in both obesity treatment and cultural conversation over the past few years.
Foundayo's key distinction is that it comes as a daily oral pill rather than a weekly injection — potentially removing a significant barrier for patients who are needle-averse or struggle to keep to an injection schedule, and offering a practical convenience for those who travel or find carrying cold-chain injector pens difficult.
In clinical development, oral GLP-1 formulations of this kind have generally shown somewhat more modest but still clinically meaningful weight-loss results compared with injectable versions. The most commonly reported side effects include nausea, diarrhoea and other digestive complaints, which tend to cluster in the first weeks of treatment and ease over time.
The approval arrives amid an ongoing debate in the UK over access to obesity treatment. While Mounjaro and similar injectables have seen high demand, questions persist about how NHS resources should be prioritised and who should be first in line; some patients have had to seek private prescriptions instead, fuelling criticism about uneven access.
Experts say an oral formulation could simplify pharmacy supply chains and improve patient adherence, particularly compared with injectable pens that require cold-chain storage and handling — a logistical advantage that could matter for rural pharmacies and stretched local health systems alike.
How — and to whom — the pill will be prescribed through the NHS still depends on cost-effectiveness assessments. The UK's health technology appraisal body is separately reviewing the long-term clinical and economic value of these drugs, a process that will determine when and at what scale the medication is folded into routine public health provision.
Obesity is recognised as a significant risk factor for heart disease, type 2 diabetes and certain cancers in the UK, and health officials view wider access to effective treatments as a public health priority. Some health economists also point to the potential for reducing the NHS's long-term financial burden from chronic conditions linked to obesity.
Eli Lilly is working to scale up production of the pill to meet global demand, with the company hoping oral options give it a competitive edge in the crowded GLP-1 market. Industry analysts expect oral formulations to become a key growth driver for the sector in the years ahead.
The approval represents more than a single product launch — it's being read as a signal that obesity treatment may be shifting from injection to tablet form, a change that could fundamentally reshape access and adherence to treatment across the health system.
Read next
What is the Galleri test, and can a single blood draw really detect dozens of cancers?
Grail's Galleri test promises to screen a single blood sample for early signals of dozens of cancer types. As a US FDA advisory panel weighs the test, scientists caution that early evidence is promising but not yet conclusive.
How much strength training do you really need for a longer life?
A new study finds that just 90 to 120 minutes of strength training a week is linked to a 13% lower risk of early death, with the reduction climbing to around 45% when paired with regular aerobic exercise. The findings point to a clear "sweet spot" for longevity.
We know sleep, exercise and diet are vital for health. But why?
Sleep, exercise and diet have been treated for decades as separate prescriptions. New neuroscience research suggests the three habits produce remarkably similar effects on the brain and body, converging on a shared cellular mechanism.
What is a DXA scan, and do you need one for bone health?
A DXA scan is a quick, painless imaging test that uses low-dose X-rays to measure bone density. It's most often used to assess osteoporosis risk in people over 60, though it is increasingly popular among younger adults interested in body composition.
England on track to become one of the first countries to eliminate hepatitis C
England is on track to become one of the first countries in the world to eliminate hepatitis C, a liver-damaging virus, health officials say. Widescale testing and modern antiviral treatment have driven down new infections and deaths over the past decade.